Abingdon Health Plc · LSE:ABDX
Abingdon Health — H1 FY26 Earnings Presentation
19 slides from Abingdon Health's earnings presentation, Mar 17, 2026
Slide 1: Half-Year Results to 31 December 2025
HALF-YEAR RESULTS to 31 December 2025 Fast-tracking diagnostics and devices to improve lives LSE AIM: ABDX 1
Slide 2: Presenting team
Presenting team Dr Chris Hand Tom Hayes Executive Chairman CFO Board Member Board Member • Joined Abingdon Health in January 2025 • Co-founder of Abingdon Health • 10 years as Group Finance Director at • 30+ years’ experience in the medical Northern Bear plc, an AIM-listed Group of diagnostics indus
Slide 3: Abingdon Health plc
Abingdon Health plc W HO W E A RE F ULL S ERVICE O FFERING • Mission: Fast-tracking diagnostics and devices to improve lives • Founded in 2008, headquartered in York, UK; laboratory facilities in Doncaster UK, with US headquarters in Madison, Wisconsin • Specialist lateral flow CDMO in UK & USA • Fu
Slide 4: Financial Summary
Financial Summary H1 FY26 | Six months ended 31 December 2025 REVENUE & GROWTH C AS H & C AP I T AL • Total H1 FY26 revenues up 45% to £4.5m (H1 FY25: • Placing and retail offer in October 2025 raising £3.1m), including grant-funded income £3.2m net of expenses to accelerate US expansion and support
Slide 5: Commercial and Operational Highlights
Commercial and Operational Highlights H1 FY26 Including post-period end C O M M E R C I AL O P E R AT I O N AL • Continued strong revenue growth driven by • Further expansion of US CDMO operations in Madison, integrated, end-to-end CDMO and regulatory service Wisconsin with additional investment pla
Slide 6: US$2.5m Contract Award
US$2.5m Contract Award Development of Clinical Self-Test | 12 March 2026 C O N T R AC T D E T AI L S SCOPE OF WORK • End-to-end project management across three • US$2.5m contract value for project management and phases: expert technical support • Feasibility • Services Agreement with a UK-based cust
Slide 7: Financial Summary
Financial Summary H1 FY26 | Six months ended 31 December 2025 TOTAL REVENUE INCL. GRANT FUNDED REPORTED REVENUE ADJ. EBITDA LOSS CASH AT 31 DEC 2025 £4.5m £4.2m £1.7m £3.7m ↑ 45% vs H1 FY25 ↑ 37% vs H1 FY25 Improved from £1.9m vs £1.9m at Jun 2025 REVENUE BY SEGMENT (£'000) REVENUE BY GEOGRAPHY — H1
Slide 8: Multi-year revenue summary
Multi-year revenue summary FY22–FY26E | £’000 | FY22 excludes COVID-19 revenues 14000 KEY METRICS £12.2m 12000 +40% +45% Revenue CAGR 10000 FY22–FY25 £8.4m 8000 +37% +45% £6.1m FY26E revenue 6000 growth vs FY25 +52% £4.0m 4000 £12.2m +128% FY26E (broker estimate) £1.8m 2000 0 FY25 FY22 FY23 FY24 FY2
Slide 9: USA – OTC Markets
USA – OTC Markets • US Market Listing – Abingdon Health (OTCQB: ABDXF) will begin trading on the OTCQB Venture Market in the US next month, making shares available to US investors in dollars during US trading hours • Increased Liquidity – The OTCQB listing is expected to attract a broader investor b
Slide 10: Strengthened Group Management
Strengthened Group Management via internal promotions Natalie Thrush Candice Vendettuoli Chief of Staff Chief Delivery Officer Head of HR Head of QARA • Joined Abingdon Health February 2021 • Joined Abingdon Health July 2020 • 20+ years driving operational excellence across • 15+ years in regulated
Slide 11: Lateral Flow Technology is Evolving
Lateral Flow Technology is Evolving Lateral flow is a powerful, rapid, flexible, on-site diagnostic technology: ▪ Single biomarker or multiplex capability ▪ Qualitative or quantitative ▪ Multiple sample matrices ▪ Competitive or sandwich assay format ▪ Gold, latex, carbon, polystyrene bead, fluoresc
Slide 12: Advances: Reducing Plastic Waste
Advances: Reducing Plastic Waste 2024: $8.5 billion market 2035: $25.8 billion market* Clinical Testing Veterinary Diagnostics Clinical Testing Veterinary Diagnostics Food Safety & Environment Food Safety & Environment Drug Development & Quality Drug Development & Quality Pregnancy Testing falls wit
Slide 13: LFT use in Companion Diagnostics
LFT use in Companion Diagnostics Role of Companion Diagnostics (CDx): ▪ CDx tools provide essential data to safely and effectively use specific therapeutic products at point of care. Regulatory and Validation Requirements: ▪ Lateral flow CDx devices require rigorous validation and must demonstrate
Slide 14: CDx Application Opportunities
CDx Application Opportunities Oncology Infectious Neurology Disease CDx Inflammation and Cardiology Autoimmunity Fast-tracking diagnostics and devices to improve lives LSE AIM: ABDX 14
Slide 15: CDx Regulatory Synchronisation
CDx Regulatory Synchronisation FDA and EMA require CDx approval simultaneously with - or before - the companion therapeutic. Late CDx development is the single most common cause of delayed drug approvals. DRUG PROGRAMME NDA / BLA SYNCHRONISED Phase I Phase II Phase III Approval Submission APPROVAL C
Slide 16: Example CDx Development Timeline
Example CDx Development Timeline 2026 2027 2028 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 Drug Timeline Phase 1b/2a Phase 3 Operationally same clinical study, but separate regulatory submissions for CDx and CDx Development Po
Slide 17: Abingdon Health USA, Inc.
Abingdon Health USA, Inc. • Abingdon Health USA, Inc entity was established with commercial office and R&D laboratories fully operational at the Madison, WI, facility as of April 2025 and overseen by Abingdon co-founder, Chris Yates • An increasing number of Abingdon clients are US-based with explic
Slide 18: Summary Highlights H1 FY26
Summary Highlights H1 FY26 Including post period 1 Revenues up 45% to £4.5M in H1 FY26. Adjusted EBITDA loss reduced to £1.7M (H1 FY25: £1.9M) 2 US$2.5M Contract win announced 12 March 2026 3 US Manufacturing Expansion Underway in Madison, Wisconsin 4 OTCQB Listing Imminent: Opening ABDXF to US Inve
Slide 19: Any Questions?
Any Questions? Nina Garrett: nina.garrett@abingdonhealth.com Abingdon Health: diagnostics Fast-tracking Design | Development | Manufacturing and devices | Packaging to improve lives| Performance Evaluation| Regulatory LSESupport AIM: ABDX 1919